Award
National Cancer Institute 5U54CA274513-04
Project 1 Genetic and Immunologic Mechanisms Underlying Combination Sacituzumab plus Radiation Therapy for Bladder Cancer
Recipient
Cleveland Clinic Lerner COM-CWRU
Award Amount
$193,244.00
Ceiling
$193,244.00
Awarded
September 15, 2025
Identifier
5U54CA274513-04
This NIH-funded project investigates the genetic and immune mechanisms affecting bladder cancer treatment efficacy and resistance, comparing sacituzumab plus radiation therapy to cisplatin plus radiation to optimize therapeutic strategies.
Description
Research Project 1 focuses on understanding the genetic and immunologic mechanisms underlying the efficacy and resistance of bladder cancer treatments, specifically comparing sacituzumab govitecan (SG) antibody-drug conjugate plus radiation versus cisplatin plus radiation. The study aims to elucidate molecular, genetic, and immune effects, characterize tumor clonal dynamics, and investigate mechanisms of acquired resistance.